An engineered anti-Oropouche virus human-murine chimeric immunoglobulin M is a viable substitute for positive human serum controls in diagnostic serology assays Authors: Kerri L Miazgowicz, Christin H Goodman, Amanda E Calvert, Daniel Limonta, Daniel Limonta, David Safronetz, Stephanie Seifert, Daniel Limonta, Stephanie Seifert, Daniel Limonta Published: 2026 ABSTRACT AbstractOropouche virus (OROV) is an arbovirus of concern due to its recent geographical expansion and association with teratogenic outcomes. Serodiagnosis of OROV infection relies on methods such as the immunoglobulin M antibody-capture enzyme-linked immunosorbent assay (MAC-ELISA) and the plaque reduction neutralization test (PRNT). For re-emerging viruses such as OROV, sourcing large quantities of sera from acutely infected human donors for use as positive-control assay material is a significant challenge and hinders diagnostic capacity. To overcome this, we engineered and produced OROV119-chIgM, a human-murine chimeric IgM (chIgM) that expresses the variable regions of the murine monoclonal antibody OROV119, reactive to the Gc protein of OROV, on a human IgM backbone. OROV119-chIgM was evaluated in PRNT and MAC-ELISA to determine its suitability as a positive control in each assay. In PRNT, OROV119-chIgM achieved neutralization equivalent to an OROV polyclonal mouse hyperimmune ascitic fluid (MHIAF). Further, OROV119-chIgM exhibited superior performance compared with OROV-positive human donor sera in a MAC-ELISA. Overall, OROV119-chIgM is an attractive alternative to human donor sera assay control material because of its long-term sustainability and consistent batch-to-batch potency. OROV119-chIgM enhances diagnostic capacity by ensuring laboratories are poised to respond rapidly to future OROV outbreaks. Introduction The re-emergence of Oropouche virus (OROV) in 2023–2025 in the Americas was notable due to high case counts [1], geographical expansion beyond previous outbreak regions [2], and the identification of atypical disease manifestations, including possible teratogenic outcomes (reviewed in [3,4]). The overlap among other pathogenic agents that cause non-specific febrile symptoms circulating in the region emphasizes the need for a definitive diagnostic test for OROV. OROV infection exhibits transient viremia with 60% of patients experiencing relapsing fever within 10 days of first symptom onset; thus initial molecular detection methods need to be performed in a relatively short window within seven days of symptom onset [5,6]. In contrast, serological diagnostics rely on detecting virus-specific antibodies elicited shortly after infection that persist for weeks to months, depending on the immunoglobulin class [5,7]. Serological diagnostic methods for arboviruses, such as OROV, include immunohistochemistry [8], the human IgG-ELISA [9], human IgM capture ELISA (MAC-ELISA) [10–12], and the plaque reduction neutralization test (PRNT) [13]. The MAC-ELISA detects OROV-specific IgM antibodies, a likely indicator of recent infection. PRNT detects anti-OROV neutralizing antibodies and is highly virus-specific. However, PRNT is not widely performed in all laboratories because it requires infectious virus and dedicated cell culture facilities. Serodiagnostic assays require positive and negative controls to ensure the validity of test performance (CLIA, 42 CFR 493.1256). For reemerging viruses such as OROV, sourcing large quantities of sera from previously infected human patients to use as controls and correcting for assay performance variation between serum donors is a significant challenge. Murine monoclonal antibodies (MAbs) are not suitable for use in the MAC-ELISA, as the assay capture antibody specifically binds to human Fcµ. Thus, an anti-OROV-specific neutralizing MAb with a human Fcµ is an attractive alternative. To address the need for a sustainable and consistent source of positive control material for both OROV IgM and neutralization serodiagnosis, we engineered a human-murine chimeric immunoglobulin M (chIgM) that neutralizes OROV in PRNT and efficiently captures OROV viral antigen in MAC-ELISA, circumventing the need for positive human donor sera. Results Production of OROV-specific human-murine chimeric IgM Murine hybridomas producing IgG antibodies recognizing OROV epitopes were generated by BALB/cJ inoculation with purified UV-inactivated OROV (FL-240023). Hybridoma clone OROV119, which produces potent neutralizing anti-OROV MAbs, was selected to engineer a human-murine chimeric IgM (chIgM) as positive control material for serodiagnostic assays. To construct the chIgM expression vector, the sequences of the heavy (Hv) and light (Lv) chains of the murine IgG OROV119 were determined by targeted amplification and cloned into a human IgM/kappa expression vector [14]. OROV119-chIgM was transiently expressed in human Expi293F cells, purified, and its performance was assessed in PRNT and MAC-ELISA. OROV119-chIgM retains neutralization activity against OROV To assess neutralization activity of the engineered antibody, 2-fold dilutions of 5 µg/mL purified OROV119-chIgM were tested in triplicate in PRNT (Table 1). Dose-dependent neutralization was observed for both OROV119-chIgM and OROV MHIAF positive control polyclonal sera, but not for the negative-control sample, OROV106 MAb. Both neutralization potency metrics of OROV119-chIgM were consistent with a PRNT50 value of 625 ng/mL and an IC50 of 557.6 ng/mL (Table 1 and Fig 1). Almost five times the amount of chIgM is required to achieve 90% neutralization regardless of the metric. Overall, OROV119-chIgM achieved similar levels of neutralization as OROV-specific MHIAF polyclonal sera tested at 1:1000–1:4000 dilutions (Table 1). Table 1Evaluation of OROV119-chIgM in a PRNT.Test SeraAmount (ng/mL)Percent NeutralizationOROV119-chIgM50009525008712507562557312.534156.251778.125-1439.0625-28OROV MHIAF(positive control)sera diluted 1:100096sera diluted 1:200087sera diluted 1:400064OROV 106(negative control)5000-182500-7125014 Evaluation of OROV119-chIgM in a PRNT. Neutralization reactivity of OROV119-chIgM with OROV (FL-240023). Percent neutralization of purified OROV119-chIgM was calculated based on virus input. A virus neutralization curve was generated as described in Materials and Methods. The dotted line represents 50% neutralization (IC50). OROV119-chIgM efficiently captures OROV antigen in a MAC-ELISA In the MAC-ELISA, only molecules containing human Fcµ are captured in the first step of the assay, allowing for discrimination of recent (IgM) and prior infections (IgG or other Ig classes). Thus, OROV119-chIgM can be used as a positive control in MAC-ELISA, as the antibody was engineered to contain human Fcµ with OROV specificity conferred by the murine variable regions. Compared to the positive human OROV IgM serum (laboratory-confirmed positive by diagnostic PRNT), OROV119-chIgM was more reactive at dilutions of 1:10–1:640 (chIgM: OD 1.919-1.035 vs. human sera: 0.667, along with respective P/N values) using concentrated transfection cell culture supernatant (Table 2). Furthermore, OROV119-chIgM exhibited less background reactivity to normal cell culture antigen across all dilutions tested between 1:10 and 1:5120 (OD: 0.005-0.008) compared to positive human serum (OD: 0.042) or negative human serum (OD: 0.016) tested at a 1:400 dilution, leading to higher negative background reactivity (NBR) values (Table 2) [15]. Overall, OROV119-chIgM exhibited improved MAC-ELISA assay performance characteristics at higher dilutions than the human positive control serum. Additionally, OROV119-chIgM showed high specificity to OROV, as no reactivity was detected with other viral antigens tested in the MAC-ELISA (Table 3). Table 2Evaluation of OROV119-chIgM in a MAC-ELISA.Test SeraDilutionOD450 OROV AgOD450 Normal AgP/N1NBR2Interpretation3OROV119-chIgM1:101.9190.00695.96302.24POSITIVE1:202.0160.007100.81294.341:401.9160.00795.82275.731:801.8110.00590.53344.891:1601.7970.00689.86323.811:3201.6470.00682.34291.461:6401.0350.00851.75130.181:12800.6370.00731.8789.141:25600.3180.00615.8852.501:51200.1880.0079.4025.57human sera(positive control)1:4000.6670.04233.7416.00POSITIVEhuman sera(negative control)1:4000.0200.0161.001.25NEGATIVE1P/N: Mean OD of the sample with OROV antigen (P)/ Mean OD of the negative control with OROV antigen (N).2NBR (normal background ratio): Mean OD of the sample with OROV antigen/ Mean OD of the sample with normal antigen.3Interpretation: Both P/N and NBR values are taken into consideration with interpretation defined as: POSITIVE (P/N ≥ 3.0 & NBR ≥ 2.0), EQUIVOCAL (P/N ≥ 2.0 OR < 3.0 & NBR ≥ 2.0), NEGATIVE (P/N < 2.0 & NBR any), and UNINTERPRETABLE (P/N ≥ 2.0 & NBR < 2.0). Evaluation of OROV119-chIgM in a MAC-ELISA. 1P/N: Mean OD of the sample with OROV antigen (P)/ Mean OD of the negative control with OROV antigen (N). 2NBR (normal background ratio): Mean OD of the sample with OROV antigen/ Mean OD of the sample with normal antigen. 3Interpretation: Both P/N and NBR values are taken into consideration with interpretation defined as: POSITIVE (P/N ≥ 3.0 & NBR ≥ 2.0), EQUIVOCAL (P/N ≥ 2.0 OR < 3.0 & NBR ≥ 2.0), NEGATIVE (P/N < 2.0 & NBR any), and UNINTERPRETABLE (P/N ≥ 2.0 & NBR < 2.0). Table 3Cross-reactivity of OROV119-chIgM with viral antigen in the MAC-ELISA.Antigen TypeCHIKVMAYVVEEVDENVYFVZIKVJCVLACVSSHVOROVNormalPositive serum OD11.1610.5141.1071.3090.6091.8561.6651.0351.4371.0000.0323Negative serum OD20.0230.0230.0960.0180.0380.0180.0810.0490.0380.0300.030cIgM OROV1191:1000.0140.0170.0560.0070.0210.0120.0210.0260.0202.0470.0121:2000.0110.0160.0440.0050.0150.0070.0210.0330.0171.8200.0081:4000.0120.0140.0440.0060.0130.0080.0220.0280.0201.4300.0081:8000.0120.0130.0390.0050.0120.0070.0200.0280.0200.9930.0081:16000.0140.0170.0160.0080.0180.0100.0200.0310.0210.5790.0101:32000.0130.0170.0440.0060.0160.0080.0210.0260.0200.3750.0071OD (450 nm) of virus-specific positive serum dilutions to achieve an OD (450nm) reading between 0.5 and 2. Variations are based on the antigen being tested.2OD (450 nm) of negative serum diluted 1:400 and tested on viral antigen.3OD (450 nm) of OROV-positive serum diluted 1:400 tested on normal antigen. Cross-reactivity of OROV119-chIgM with viral antigen in the MAC-ELISA. 1OD (450 nm) of virus-specific positive serum dilutions to achieve an OD (450nm) reading between 0.5 and 2. Variations are based on the antigen being tested. 2OD (450 nm) of negative serum diluted 1:400 and tested on viral antigen. 3OD (450 nm) of OROV-positive serum diluted 1:400 tested on normal antigen. Discussion A chimeric murine-human IgM monoclonal (OROV119-chIgM) was engineered to provide a consistent and sustainable source of positive control material for serological assays (PRNT and MAC-ELISA) detecting OROV-specific antibodies in human sera. Incorporation of OROV119-chIgM as positive control material in serological assays eliminates the need to acquire and consume limited human sera from OROV-infected individuals, as has been developed for several other arboviruses [10,16–19]. OROV119-chIgM potently neutralized a recent isolate of OROV (FL-240023) in PRNT and efficiently captured OROV viral antigen in a MAC-ELISA comparable to the limited pooled human sera control tested. By engineering OROV specificity onto a human Fcµ molecule, OROV119-chIgM is suitable for use in the MAC-ELISA, which discriminates recent exposure from prior infection. OROV119-chIgM can be utilized in other serological applications compatible with human IgM molecules that include OROV Gc protein, such as IFA or flow cytometry. The performance of an engineered monoclonal antibody (OROV119-chIgM) as positive control material was compared to polyclonal MHIAF in a PRNT or a limited pool of natural polyclonal OROV-positive human sera in a MAC-ELISA. In both assay formats, sera-derived antibodies are being tested for their ability to interact with assay-defined viral antigens. Thus, while the resilience of OROV119-chIgM to detect OROV epitopes across viral variants is currently unknown and warrants a thorough examination of the MAb epitope region, diagnostic assay performance is not substantially affected by natural viral evolution. During outbreak responses, it is infeasible to match the test viral antigen to current variants exactly because of the extensive performance characterizations that are mandated for each diagnostic test. Therefore, OROV119-chIgM would need to be tested against the selected antigen in each laboratory-developed test. Regardless, strong reactivity of OROV119-chIgM with the original 1955 OROV strain (TRVL-9760) viral antigen and its ability to potently neutralize a recent OROV strain from 2024 (FL-240023) implicates robust epitope conservation amid natural viral evolution through the most recent outbreak. The ability of OROV119-chIgM to bind future OROV variants is currently unknown but could be monitored and evaluated with genetic sequences from newly identified positive cases. Work is currently ongoing to develop a cell line constitutively expressing OROV119-chIgM for continual production. While this work is in progress, we have shown that transient transfection can be relied upon to produce small batches of antibody, and production of OROV119-chIgM can be readily scalable to produce large quantities of antibody. For example, a single 50 mL small batch culture of OROV119-chIgM could support 83 PRNTs using 10 µg/mL stocks (PRNT90) or >100,000 MAC-ELISA tests using a 1:640 dilution (P/N 51.75). Thus, large production batches are suitable for extended use, as each liter of OROV119-chIgM culture can support >1,000 PRNT or >2,000,000 MAC-ELISA tests. OROV119-chIgM was developed for use as a test control in diagnostic assays to confirm the assay was performed properly. Considerations for the implementation and use of OROV119-chIgM as assay positive control material should be made on a case-by-case basis. Each testing laboratory should thoroughly validate assays in accordance with their institutional and accrediting body regulations to ensure proper overall test performance. The long-term stability of OROV119-chIgM reactivity in various conditions is currently being evaluated for use at the CDC. Laboratories implementing OROV119-chIgM as positive test control material will need to evaluate it in their own testing environments based on their requirements. OROV119-chIgM enhances laboratory capacity by providing a reagent that can be readily produced and distributed to laboratories to aid development and implementation of diagnostic serological assays with more consistent and defined positive control performance metrics. Overall, OROV119-chIgM helps ensure laboratories will be capable of responding rapidly to future OROV outbreaks by eliminating the need for limited and varied human sera for use as control material. Materials and methods Ethics statement Ethics approval for use of previously collected human diagnostic specimens was obtained from the U.S. Centers for Disease Control’s (CDC’s) Human Subjects Institutional Review Board (CDC IRB #6773). Human specimens were delinked from any personal identifiers before the commencement of the study. Informed consent was not required in accordance with the CDC IRB determination because the study used previously collected, de-identified specimens. Mice were handled as specified by the Division of Vector-Borne Diseases Institutional Animal Care and Use Committee recommendations (Protocol #25–001). Viruses and viral antigen OROV isolate FL-240023 was acquired from the CDC Arbovirus Reference Collection (ARC) in Fort Collins, Colorado. Vero cells acquired from the CDC Arboviral Diagnostic Reagent Team (DRT) were maintained in DMEM supplemented with 5% FBS, pen/strep, and L-glutamine at 37°C and 5% CO2. Virus stocks were propagated once in Vero cells and supplemented with 20% FBS for storage. Virus purification was performed using a 30% glycerol-45% potassium tartrate gradient [20] and resuspended in 0.2M Tris (pH 8.0). Virus was inactivated using a UV Crosslinker (VWR) for 15 mins (585,000μJ/cm). Viral titers and inactivation were confirmed with one passage of virus in a standard plaque assay on Vero cells [21]. Viral and normal antigens for MAC-ELISAs were acquired from the CDC Arboviral Reference Collection. These antigens were derived from inactivated infected, VLPs, or uninfected cell-culture supernatants. All antigens were cell culture-derived except for VEEV antigen, which was derived from suckling mouse brain. Hybridoma generation BALB/cJ (strain 000651) mice were purchased from The Jackson Laboratory and housed at the CDC animal facility in Fort Collins, CO, in accordance with CDC IACUC protocol #22–002. After a two-week acclimation period, mice were inoculated intraperitoneally four times, four to five weeks apart, with purified UV-inactivated OROV (FL-240023) mixed 1:1 with enhanced magic mouse adjuvant (CDN-A001E, Creative Diagnostics). The first inoculation contained 11 µg of virus, while subsequent inoculations contained 50 µg. Fusions were performed four days after the final boost using murine splenocytes with P3X63Ag8.632 murine myeloma cells following instructions in the ClonalCell HY Hybridoma cloning kit (03800, StemCell) and electrofusion in a 10mm gap BTX microslide using 39V alignment, with 2 pulses of AC: 30 sec and a 10 µs DC: 3000V. Hybridoma clone OROV119 was selected for chimerization based on its ability to neutralize OROV in a PRNT screen. OROV119-chIgM engineering and production Signal sequences and heavy and light chain variable sequences of murine hybridoma OROV119 were determined by a murine IgG- and kappa-specific nested PCR using complementary DNA generated from messenger RNA, as previously described [22] (S1 Fig). PCR amplicons were sequenced using Oxford Nanopore sequencing (Plasmidsaurus). Human-murine chimeric IgM antibody (chIgM) was generated by PCR from a bicistronic mammalian expression vector, hIgM/kappa-pVITRO1 (61881, Addgene) [14] and combined with synthesized (Twist Bioscience) murine OROV119 heavy and light chain variable regions containing vector end compatibility using HiFi DNA Assembly 2X Master Mix (E5520S, NEB). Engineered plasmids were verified by full-length Oxford Nanopore sequencing (Plasmidsaurus) before transient transfection was performed using ExpiFectamine 293 Transfection Kit (A14524, ThermoFisher Scientific) with Expi293F cells (A14528, ThermoFisher Scientific) maintained in vented flasks shaken at 120 rpm at 37°C with 8% CO2. Transfection enhancers were added one day post-transfection, and cell supernatant was collected five days post-transfection. Cell-culture supernatant was concentrated using centrifugal filters (UFC701008, Millipore Sigma), followed by purification with the Pierce IgM purification kit (44897, ThermoFisher). Purified OROV119-chIgM concentrations were determined at 280nm using a NanoDrop OneC spectrophotometer. Plaque reduction neutralization test (PRNT) To assess neutralization activity, purified OROV119-chIgM was tested in triplicate in PRNT. Approximately 75 PFU of OROV (FL-240023) were incubated with equal volumes of 2-fold dilutions of purified MAb starting at 10,000 ng/ml in BA1 (Hanks M-199 salts (M9163, Sigma-Aldrich), 0.05MTris pH 7.6 (15567027, Gibco), 1% BSA (81-066-4, Millipore), 0.35 g/L sodium bicarbonate (25080–094, Gibco), 100 U/mL penicillin, 100 mg/L streptomycin (15140–122, Gibco), 1 mg/L fungizone (SV30078.01, Hyclone) [19] for one hour at 37oC, 5% CO2. Anti-OROV MHIAF was used as a positive control (CDC ARC), and an anti-OROV murine IgG MAb without neutralization activity (OROV106) was used as a negative control. Six-well plates of Vero cells were inoculated with the virus-Ab complexes and incubated at 37°C, 5% CO2 for one hour after which cells were overlaid with 3 mL of nutrient agarose overlay (1% SeaKem LE agarose (50004, Lonza) in nutrient medium (0.165% lactalbumin hydrolysate (259962, VWR), 0.033% yeast extract (212750, ThermoFisher Scientific), Earle’s balanced salt solution, and 2% FBS) [16]. After incubation at 37°C, 5% CO2 for 48 hours, a second overlay containing 80 µg/ml of neutral red vital stain (091691149, MP Biomedicals) was applied. Plaques were counted 72 hours after infection, and percent neutralization was calculated based on input virus titer. PRNT50 and PRNT90 values were determined as the dilution of sera or concentration of MAb that achieved 50% or 90% reduction in input virus. A virus neutralization curve of OROV119-chIgM was generated by a 4-parameter non-linear regression dose-response and used to calculate the 50% inhibitory concentration (IC50) with the bottom and top of the curve constrained to 0 and 100, respectively (GraphPad Prism, v. 10) (S1 File). Human IgM capture ELISA (MAC-ELISA) Concentrated OROV119-chIgM transfected cell culture supernatant was tested in MAC-ELISA as previously described [10]. Briefly, goat anti-human IgM (5210–0157, SeraCare) was diluted 1:2000 in carbonate/bicarbonate buffer, and coated plates were incubated overnight at 4˚C. Unbound antibody was removed, and nonspecific binding sites were blocked with 5% nonfat dry milk in PBS (0.5% Tween-20) for 30 minutes at room temperature. Plates were washed five times with PBS (0.1% Tween-20) wash buffer after each step in the assay, except for the wash after the conjugate step, where plates were washed ten times. OROV119-chIgM was serially diluted 2-fold in wash buffer, and OROV-IgM-positive and negative human samples were diluted 1:400 in wash buffer and added to the plate. For cross-reactivity testing, the following IgM positive serum control samples (CDC Human Subjects IRB protocol #6773) were diluted 1:150–1:3000 in wash buffer, depending on the viral antigen being tested, and added to the plate: chikungunya virus (CHIKV), Mayaro virus (MAYV), Venezuelan equine encephalitis virus (VEEV), dengue virus (DENV), yellow fever virus (YFV), Zika virus (ZIKV), Jamestown canyon virus (JCV), La Crosse virus (LACV), and Snowshoe hare virus (SSHV). After incubation of antibody at 37°C for one hour, OROV-, CHIKV, MAYV, VEEV, DENV, YFV, ZIKV, JCV, LACV, and SSHV positive or OROV-normal antigens were added and incubated overnight at 4˚C. Peroxidase-conjugated OROV MAb (for OROV and normal antigens), cross-reactive alphavirus MAb (for CHIKV, MAYV, VEEV antigens), cross-reactive flavivirus MAb (for DENV, YFV, ZIKV antigens), and cross-reactive orthobunyavirus MAb (for JCV, LACV, SSHV antigens) were incubated on the plate for one hour at 37°C. Enhanced K-blue TMB substrate (308175, Neogen) was added to each well, and plates were incubated in the dark at room temperature for 10 minutes. The reaction was stopped with TMB Stop solution (5150–0021, SeraCare), and plates were read at 450 nm (S2 File). Supporting information Nucleotide and deduced amino acid sequences of MAb OROV119 variable regions. (A) variable region of the heavy chain. (B) variable region of the kappa chain. MAb OROV119-specific signal sequences are shown in aqua. Framework regions (FR) 1, 2, 3, and 4 are shown in yellow. Complementarity determining regions (CDR) 1, 2, and 3 are shown in blue. (DOCX) PRNT data used to calculate PRNT50, PRNT90 and IC50 of OROV119-chIgM. (XLSX) (A) MAC-ELISA data generated to determine virus cross-reactivity of OROV119-chIgM with other arboviruses. (B) Table of reagents used in MAC-ELISA detailing source of the reagent, catalog number, and dilution used in the assay. (XLSX) Acknowledgments We would like to thank the Arbovirus Reference Collection (ARC) at the Centers for Disease Control and Prevention (CDC) in Fort Collins, Colorado, for supplying the virus stocks, control sera, and antigen used in this study. Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. Data Availability All relevant data from this study has been included in the manuscript and supplementary files. Funding Statement The author(s) received no specific funding for this work. References 22 Jun 2026 PNTD-D-26-00958 An Engineered Anti-Oropouche Virus Human-Murine Chimeric Immunoglobulin M is a Viable Substitute for Positive Human Serum Controls in Diagnostic Serology Assays PLOS Neglected Tropical Diseases Dear Dr. Calvert, Alternative serological diagnostic approaches for Oropouche virus (OROV) infection have not been extensively evaluated during previous outbreaks. With the explosive spread in the Americas of the novel reasssortant of OROV recently reported in the Brazilian Amazon, further research aimed at improving serodiagnostic tools is warranted. In this study, Miazgowicz et al engineered and tested a human-murine chimeric IgM against the Gc protein of OROV in PRNT and MAC-ELISA to be used as a potential substitute of positive control sera. Thank you for submitting your manuscript to PLOS Neglected Tropical Diseases. After careful consideration, we feel that it has merit but does not fully meet PLOS Neglected Tropical Diseases's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. The submitted manuscript includes two tables in the main text. Addressing the reviewers’ comments may provide opportunities to expand the data presentation and discussion, ultimately enhancing the rigor and significance of the work. Please submit your revised manuscript within by Aug 21 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosntds@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pntd/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: * A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below. * A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. * An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Daniel Limonta, MD, PhD Academic Editor PLOS Neglected Tropical Diseases David Safronetz Section Editor PLOS Neglected Tropical Diseases Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-4304-636XX Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-1765-0002 Additional Editor Comments (if provided): Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 1) Thank you for including an Ethics Statement for your study. Please include: i) A statement that formal consent was obtained (must state whether verbal/written) OR the reason consent was not obtained (e.g. anonymity). NOTE: If child participants, the statement must declare that formal consent was obtained from the parent/guardian.]. 2) When completing the data availability statement of the submission form, you indicated that you will make your data available on acceptance. We strongly recommend all authors decide on a data sharing plan before acceptance, as the process can be lengthy and hold up publication timelines. Please note that, though access restrictions are acceptable now, your entire data will need to be made freely accessible if your manuscript is accepted for publication. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If you are unable to adhere to our open data policy, please kindly revise your statement to explain your reasoning and we will seek the editor's input on an exemption. Please be assured that, once you have provided your new statement, the assessment of your exemption will not hold up the peer review process. 3) In the online submission form, you indicated that All relevant data from this study will be made available upon study completion.. All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 1. In a public repository 2. Within the manuscript itself 3. Uploaded as supplementary information. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons by return email and your exemption request will be escalated to the editor for approval. Your exemption request will be handled independently and will not hold up the peer review process, but will need to be resolved should your manuscript be accepted for publication. One of the Editorial team will then be in touch if there are any issues. 4) We have amended your Competing Interest statement to comply with journal style. We kindly ask that you double check the statement and let us know if anything is incorrect. Reviewers' Comments: Reviewer's Responses to Questions Key Review Criteria Required for Acceptance? As you describe the new analyses required for acceptance, please consider the following: Methods -Are the objectives of the study clearly articulated with a clear testable hypothesis stated? -Is the study design appropriate to address the stated objectives? -Is the population clearly described and appropriate for the hypothesis being tested? -Is the sample size sufficient to ensure adequate power to address the hypothesis being tested? -Were correct statistical analysis used to support conclusions? -Are there concerns about ethical or regulatory requirements being met? Reviewer #1: Major technical comments: PRNT: In lines 102–105, the comparisons presented are not meaningful, as a purified monoclonal preparation cannot be directly compared to a polyclonal serum sample. A more appropriate approach would be to dilute the chimeric IgM (chIgM) in negative human serum to achieve concentrations comparable to those expected in clinical samples. A similar issue is present in the ELISA experiments. The chIgM is tested as unpurified supernatant and compared directly to human samples. This is not a like-for-like comparison. Using purified chIgM diluted in negative human serum would have provided more meaningful results. Therefore, the statement in lines 121–123 is not adequately supported, given the limitations of the experimental design. Minor comments: Ethics statement: Please clarify whether the human positive serum was collected specifically for this study or obtained from previously published work. Additionally, indicate whether donors were laboratory-confirmed positive for OROV infection. Hybridoma generation: Please include details on: The amount of antigen used for immunisation The method of virus inactivation The immunisation schedule (number of boosts, timing between immunisations, etc.) IgM capture ELISA: Clearly define the OROV antigen (OROV-Ag) and the normal antigen (Normal Ag) used in the assay. Serum dilution: Please justify the choice of a starting dilution of 1:400 for human serum samples. Was this due to limited sample volume or another reason? Reviewer #2: The methodology is clearly laid out and follows the objectives of the study. However, there are a few concerns that should be addressed: Line 91: were the sequences for the heavy and light chains deposited on Genbank or another repository? Was the chimeric IgM tested against other orthobunyaviruses for specificity? Line 206: Did you factor in extinction coefficient when determining the protein concentration on the nanodrop? Or was this measurement a generic approximation? Reviewer #3: (No Response) ********** Results -Does the analysis presented match the analysis plan? -Are the results clearly and completely presented? -Are the figures (Tables, Images) of sufficient quality for clarity? Reviewer #1: see major technical comments above Q: Could the authors explain the rationale for selecting a kappa versus lambda light chain? Reviewer #2: The results, figures and tables are presented clearly. Reviewer #3: (No Response) ********** Conclusions -Are the conclusions supported by the data presented? -Are the limitations of analysis clearly described? -Do the authors discuss how these data can be helpful to advance our understanding of the topic under study? -Is public health relevance addressed? Reviewer #1: The manuscript by Miazgowicz et al. describes the production of a humanised chimeric IgM intended for use as a positive control in serological assays for Oropouche virus (OROV). My main concern with this work is conceptual. A single monoclonal antibody (mAb) is not truly commutable with a clinical sample and, importantly, may not be sufficiently resilient to viral variation. There is no characterisation of the epitope (e.g. epitope mapping), making it difficult to determine whether the antibody targets a conserved region of the virus. A polyclonal preparation, or a mixture of 3–4 monoclonal antibodies targeting different epitopes, would represent a more appropriate and robust alternative. At a minimum, I would expect the authors to acknowledge and discuss this limitation in the Discussion section. Reviewer #2: Conclusions (Discussion) section was quite short and can be expanded in terms of limitations. Reviewer #3: (No Response) ********** Editorial and Data Presentation Modifications? Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”. Reviewer #1: (No Response) Reviewer #2: (No Response) Reviewer #3: (No Response) ********** Summary and General Comments Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed. Reviewer #1: Minor issues: Line 62 (Ref 5): I was unable to find evidence supporting the statement regarding transient viremia in the cited reference. Please provide a more appropriate source. Line 67 (Refs 8–9): These are not suitable references for PRNT methodology. Both manuscripts cite other studies where PRNT was performed, but do not themselves describe the assay. Please replace with primary methodological references. Line 73: Please clarify the meaning of “CLIA, 42 CFR…”. This appears to be a typographical or formatting error. Reviewer #2: The study by Miazgowicz et al describes a recombinant, chimeric IgM mouse antibody that was humanized to work as a control in their MAC-ELISA. Although the chimeric antibody would serve useful as a control, the work presented in this manuscript reads more like a methodology paper and may be inappropriate for PLOS NTD - perhaps submission to PLOS One may be more suitable. Reviewer #3: Thank you so much for the opportunity to review this manuscript titled “An Engineered Anti-Oropouche Virus Human-Murine Chimeric Immunoglobulin M is a Viable Substitute for Positive Human Serum Controls in Diagnostic Serology Assays.” Overall, this is a technically sound, concise, methodologically clear, and timely diagnostic-development study with practical public health relevance, particularly given the recent emergence of Oropouche virus disease in the Americas. Please, find below my comments and suggestions for the authors. The Discussion currently lacks a dedicated limitations paragraph. The following should be explicitly acknowledged: 1. Validation against only one OROV isolate. 2. Limited human serum comparator panel. 3. Absence of cross-reactivity testing. 4. Lack of long-term stability data. 5. Use of transient rather than stable expression systems. 6. No inter-laboratory reproducibility assessment. 7. No field validation in endemic settings. 8. Unknown performance across evolving OROV strains. 9. Line 102: clarify whether PRNT50 and IC50 are derived independently or from the same regression model. 10. Line 176: specify whether UV inactivation was validated by serial passage. 11. Line 241: “peroxidase-conjugated OROV MAb)” contains an apparent parenthesis typo. 12. Consistently use either “chIgM” or “cIgM”; both appear in the manuscript. ********** PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] Figure resubmission: Reproducibility: To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols 24 Jul 2026 Submitted filename: PLoSNTDs_OROV_IgM_response to reviewers_final.docx 2 Aug 2026 Dear Dr. Calvert, We are pleased to inform you that your manuscript 'An Engineered Anti-Oropouche Virus Human-Murine Chimeric Immunoglobulin M is a Viable Substitute for Positive Human Serum Controls in Diagnostic Serology Assays' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases. We appreciate the authors' efforts in revising the manuscript. The responses provided adequately address the reviewers' recommendations and the manuscript has improved substantially. Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests. Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated. IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript. Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS. Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases. Best regards, Daniel Limonta, MD, PhD Academic Editor PLOS Neglected Tropical Diseases Stephanie Seifert Section Editor PLOS Neglected Tropical Diseases Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-4304-636XX Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-1765-0002 *********************************************************** p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; line-height: 16.0px; font: 14.0px Arial; color: #323333; -webkit-text-stroke: #323333}span.s1 {font-kerning: none Dear Dr. Calvert, We are delighted to inform you that your manuscript, "An Engineered Anti-Oropouche Virus Human-Murine Chimeric Immunoglobulin M is a Viable Substitute for Positive Human Serum Controls in Diagnostic Serology Assays," has been formally accepted for publication in PLOS Neglected Tropical Diseases. We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication. The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly. Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers. For Research Articles, you will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases. Best regards, Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases Supplementary Materials Nucleotide and deduced amino acid sequences of MAb OROV119 variable regions. (A) variable region of the heavy chain. (B) variable region of the kappa chain. MAb OROV119-specific signal sequences are shown in aqua. Framework regions (FR) 1, 2, 3, and 4 are shown in yellow. Complementarity determining regions (CDR) 1, 2, and 3 are shown in blue. (DOCX) PRNT data used to calculate PRNT50, PRNT90 and IC50 of OROV119-chIgM. (XLSX) (A) MAC-ELISA data generated to determine virus cross-reactivity of OROV119-chIgM with other arboviruses. (B) Table of reagents used in MAC-ELISA detailing source of the reagent, catalog number, and dilution used in the assay. (XLSX) Submitted filename: PLoSNTDs_OROV_IgM_response to reviewers_final.docx Data Availability Statement All relevant data from this study has been included in the manuscript and supplementary files.